News

Eptinezumab, Lundbeck’s intravenous monoclonal antibody that will be marketed as Vyepti, will become available for prescription in April 2020 with a recommended dose of 100 mg quarterly.

The chief science officer at the Alzheimer's Drug Discovery Foundation discussed the resource, which consists of more than 200 reports on drugs, development, supplements, food/drink, nonpharmacologics, and risk factors related to brain health.

Neurology News Network for the week ending February 22, 2020.

Despite missing the primary end point, data from a subset of patients suggest that the novel peptide may be beneficial in those who have not received alteplase.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 21, 2020.

Phenytoin is indicated for the treatment of tonic-clonic and psychomotor seizures in pediatric and adult patients.

The previously approved therapy is now indicated for treatment in pediatric patients age 2 to 10.

New data suggest a switch from natalizumab to a high efficacy disease-modifying therapy for patients with multiple sclerosis is more beneficial than switching to moderate efficacy therapy, including a lower risk of disease activity.

Despite the conventional need for patients to travel to MRI devices, the use of a point-of-care, portable scanner has proven to be a feasible method of acquiring clinically useful images.

Secondary endpoints and final results from the clinical study will be announced at the end of March 2020.

Patients 65 and under were more likely to develop seizures following a stroke than older patients.

The beneficial impact on stroke risk appeared to be greater in patients age 79 and younger than in the older patients examined.

Self-administration of the drug led to statistically significant motor status changes within 30 minutes of treatment.